[1]陆海楠,乔思雨,李绵绵,等.疏肝定悸汤加减治疗阵发性房颤疗效研究[J].陕西中医,2026,(8):1052-1056.[doi:DOI:10.3969/j.issn.1000-7369.2026.08.007]
　LU Hainan,QIAO Siyu,LI Mianmian,et al.Study on clinical efficacy of modified Shugan Dingji decoction in treatment of paroxysmal atrial fibrillation[J].,2026,(8):1052-1056.[doi:DOI:10.3969/j.issn.1000-7369.2026.08.007]
点击复制

疏肝定悸汤加减治疗阵发性房颤疗效研究

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年8期
页码:
1052-1056
栏目:
临床研究
出版日期:
2026-08-05

文章信息/Info

Title:
Study on clinical efficacy of modified Shugan Dingji decoction in treatment of paroxysmal atrial fibrillation
作者:
陆海楠1; 2; 乔思雨1; 李绵绵3; 叶庆宇4; 张懿5; 林志康6; 沈琳1
（1.上海中医药大学附属龙华医院，上海 200032；2.海军军医大学第一附属医院，上海 200082；3.厦门医学院，福建 厦门 361023；4.上海市老年医学中心，上海 201100；5.上海市闵行区中西医结合医院，上海 200241；6.上海市闵行区浦江社区卫生服务中心，上海 201108）
Author(s):
LU Hainan1; 2; QIAO Siyu1; LI Mianmian3; YE Qingyu4; ZHANG Yi5; LIN Zhikang6; SHEN Lin1
(1.Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;2.The First Affiliated Hospital of Naval Military Medical University,Shanghai 200082,China;3.Xiamen Medical College,Xiamen 361023,China;4.Shanghai Geriatric Medical Center 201100,China;5.Minhang TCM-Integrated Hospital,Shanghai 200241,China;6.Pujiang Community Health Service Center,Minhang District,Shanghai 201108,China)
关键词:
心律失常; 阵发性房颤; 肝郁气滞型; 心肝同治; 疏肝定悸汤加减
Keywords:
Arrhythmia; Paroxysmal atrial fibrillation; Liver depression and Qi stagnation; Heart-Liver simultaneous regulation; Modified Shugan Dingji decoction
分类号:
R 541.7
DOI:
DOI:10.3969/j.issn.1000-7369.2026.08.007
文献标志码:
A
摘要:
目的：回顾性评价应用疏肝定悸汤加减治疗阵发性房颤临床疗效。方法：回顾性分析肝郁气滞型阵发性房颤患者，依据是否服用疏肝定悸汤分为暴露组（西药基础治疗+疏肝定悸汤加减）与非暴露组（单纯西药基础治疗），采用1∶1倾向性评分匹配纳入各100例。观察指标包括24小时动态心电图、心脏超声、B型利钠肽（BNP）、中医证候积分及肝肾功能。结果：暴露组总有效率82.00%，高于非暴露组68.00%，差异有统计学意义（P＜0.05）。治疗后，暴露组平均心室率、房颤负荷均低于非暴露组（P＜0.05）。两组平均心室率及房颤负荷均较治疗前下降（P＜0.05）。暴露组BNP水平较治疗前降低，且低于非暴露组（P＜0.05）。非暴露组BNP治疗前后比较，差异无统计学意义（P＞0.05）。心脏超声指标中，仅非暴露组射血分数（EF）较治疗前下降（P＜0.05），其他指标组间、组内比较，差异无统计学意义（均P＞0.05）。治疗后，暴露组中医证候评分低于非暴露组（P＜0.01）。两组中医证候评分较治疗前下降（P＜0.01）。两组治疗前后肝肾功能比较，差异无统计学意义（P＞0.05）。结论：疏肝定悸汤加减可降低肝郁气滞型阵发性房颤患者的平均心室率、房颤负荷、中医证候评分、BNP水平，有助于改善临床症状、提高生活质量。
Abstract:
Objective:To retrospectively evaluate clinical efficacy of modified Shugan Dingji decoction in treating paroxysmal atrial fibrillation.Methods:A retrospective analysis was conducted on patients with liver Qi stagnation-type paroxysmal atrial fibrillation.Based on whether they received modified Shugan Dingji decoction,patients were divided into exposed group (conventional Western medicine treatment plus modified Shugan Dingji decoction) and non-exposed group (conventional Western medicine treatment alone).A total of 100 patients were included in each group using 1∶1 propensity score matching.Outcome measures included 24-hour dynamic electrocardiogram,echocardiography,B-type natriuretic peptide,traditional Chinese medicine syndrome scores,and safety indicators of liver and kidney function.Results:The overall response rate in the exposed group (82.00%) was higher than that in the unexposed group (68.00%),with statistically significant difference(P＜0.05).After treatment,the average ventricular rate and atrial fibrillation burden in the exposed group were both lower than those in the unexposed group(P＜0.05).The average ventricular rate and atrial fibrillation burden in both groups decreased compared with pre-treatment levels (P＜0.05).BNP levels in the exposed group were lower than pre-treatment levels(P＜0.05)and lower than those in the unexposed group(P＜0.05）.Changes in BNP levels in the unexposed group before and after treatment were not statistically significant (P＞0.05).Among echocardiographic parameters,only the ejection fraction in the non-exposure group decreased compared with pre-treatment levels(P＜0.05).Differences in the remaining parameters between and within groups were not statistically significant (P＞0.05).Following treatment,the total TCM syndrome scores in the exposed group significantly lower than that in the non-exposed group (P＜0.01).Total TCM syndrome scores in both groups decreased significantly compared with pre-treatment levels (P＜0.01).There were no significant abnormalities in liver or kidney function in either group before or after treatment (P＞0.05).Conclusion:Modified Shugan Dingji decoction significantly reduces atrial fibrillation burden,average ventricular rate,TCM syndrome scores,and BNP levels in patients with liver Qi stagnation-type paroxysmal atrial fibrillation,contributing to improved clinical symptoms and quality of life.

参考文献/References:

[1]中华医学会心血管病学分会,中国生物医学工程学会心律分会.心房颤动诊断和治疗中国指南[J].中华心血管病杂志,2023,51(6)：572-618.
[2]王晓明.重视老年人慢性心力衰竭的临床诊治特点[J].中华老年心脑血管病杂志,2021,23(10)：1009-1011.
[3]SHI S,TANG Y,ZHAO Q,et al.Prevalence and risk of atrial fibrillation in China：A national cross-sectional epidemiological study[J].Lancet Reg Health West Pac，2022，23（11）：100439.
[4]曹钰,柴艳芬,陈康玉,等.急性心房颤动中国急诊管理指南（2024）[J].中国急救医学,2024,44(8)：645-667.
[5]黄从新,张澍,黄德嘉,等.心房颤动：目前的认识和治疗的建议-2018[J].中国心脏起搏与心电生理杂志,2018,32(4)：315-368.
[6]郭玉冰,李冬婉,谷云飞,等.心外膜脂肪厚度及血清半乳糖凝集素-3、氧化三甲胺水平与房颤射频消融术后复发相关性分析[J].陕西医学杂志,2026,55(1)：63-67.
[7]VARZALY J A,LAU D H,CHAPMAN D,et al.Hybrid ablation for atrial fibrillation：A systematic review and meta-analysis[J].JTCVS Open，2021，16（6）：141-154.
[8]CONNOLLY S J,CAMM A J,HALPERIN J L,et al.Dronedarone in high-risk permanent atrial fibrillation[J].N Engl J Med，2011，365(24)：2268-2276.
[9]NGO L,ALI A,GANESAN A,et al.Ten-year trends in mortality and complications following catheter ablation of atrial fibrillation[J].Eur Heart J Qual Care Clin Outcomes，2022，8(4)：398-408.
[10]谭巨浪,胡晓军.中医药治疗心房颤动的临床研究进展[J].中西医结合心血管病电子杂志,2020,8(13)：163-164.
[11]陆海楠,乔思雨,张帅,等.疏肝定悸汤加减对阵发性房颤肝郁气滞型患者终点事件发生影响的回顾性队列研究[J].中医杂志,2024,65(1)：66-71.
[12]HINDRICKS G,POTPARA T,DAGRES N,et al.2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery：The task force for the diagnosis and management of atrial fibrillation of the European society of cardiology developed with the special contribution of the European heart rhythm association of the ESC[J].Eur Heart J，2021，42(5)：373-498.
[13]国家中医药管理局.中药新药临床研究指导原则(第2辑)[M].北京：中国医药科技出版社,1995：91-94.
[14]李灿东.中医诊断学[M].北京：中国中医药出版社,2016：299-300.
[15]南京中医药大学.中医内科学[M].北京：中国医药科技出版社,2007：126-135.
[16]邱月清,王振涛,王冰,等.快速性心律失常的中医研究进展[J].世界中医药,2023,18(15)：2249-2255.
[17]YANG W,WANG W,CAI S,et al.Synthesis and in vivo antiarrhythmic activity evaluation of novel scutellarein analogues as voltage-gated Nav1.5 and Cav1.2 channels blockers[J].Molecules，2023，28(21)：7417.
[18]姚雪,吴国真,赵宏伟,等.黄芩中化学成分及药理作用研究进展[J].辽宁中医杂志,2020,47(7)：215-220.
[19]牟春燕,殷越,沈子芯.当归化学成分及药理作用研究进展[J].山东中医杂志,2024,43(5)：544-551.
[20]LIU J,PEI C,JIA N,et al.Preconditioning with ginsenoside Rg3 mitigates cardiac injury induced by high-altitude hypobaric hypoxia exposure in mice by suppressing ferroptosis through inhibition of the RhoA/ROCK signaling pathway[J].J Ethnopharmacol，2025，337(2)：118861.
[21]AL-KHATIB S M,ALLENLAPOINTE N M.Rate- and rhythm-control therapies in patients with atrial fibrillation：A systematic review[J].Ann Intern Med，2014，160(11)：760-773.
[22]中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会.中国心房颤动管理指南（2025）[J].中国心脏起搏与心电生理杂志,2025,39(4)：273-343.
[23]努尔比耶·麦麦提,任澎.脑钠肽与心房颤动关系的最新研究进展[J].心血管病学进展,2019,40(6)：881-885.
[24]尚立芝,毛梦迪,许二平,等.柴胡加龙骨牡蛎汤对抑郁大鼠海马组织PI3K/Akt/GSK3β/β-catenin信号通路的影响[J].中国实验方剂学杂志,2020,26(23)：12-19.
[25]徐璐,史金玉,王超,等.基于Adam10/Notch1通路探究柴胡加龙骨牡蛎汤治疗急性心肌梗死合并焦虑疗效机制[J].陕西中医,2025,46(7)：875-880.
[26]秦国玉,曲夷,张浩,等.百合地黄汤药理作用研究进展[J].山东中医杂志,2023,42(3)：299-303.

相似文献/References:

[1]杨 敏,雷瑗琳.炙甘草汤治疗心律失常随机对照试验的Meta分析*[J].陕西中医,2019,(7):968.
　YANG Min,LEI Yuanlin..A meta-analysis of a randomized controlled trial on treatment of arrhythmia with zhilicorice decoction[J].,2019,(8):968.
[2]何海龙,谢连娣,王雅婧.心房颤动脉象研究进展[J].陕西中医,2023,(11):1650.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.038]

备注/Memo

备注/Memo:
国家科学技术部重大专项子课题（2025ZD0548304）；上海市卫生健康委员会中医药科研项目（2024QN032）；上海市科学技术委员会科研计划项目（18401971500）；林钟香上海市名中医工作室建设项目（LH02.50.002）
更新日期/Last Update: 2026-08-13